The stock of Iterum Therapeutics Plc (ITRM) has gone down by -3.60% for the week, with a -15.08% drop in the past month and a -28.19% drop in the past quarter. The volatility ratio for the week is 12.22%, and the volatility levels for the past 30 days are 8.30% for ITRM. The simple moving average for the past 20 days is -7.12% for ITRM’s stock, with a -23.20% simple moving average for the past 200 days.
Is It Worth Investing in Iterum Therapeutics Plc (NASDAQ: ITRM) Right Now?
The stock has a 36-month beta value of 2.88. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITRM is 33.83M, and at present, short sellers hold a 3.67% of that float. On April 29, 2025, the average trading volume of ITRM was 415.49K shares.
ITRM) stock’s latest price update
Iterum Therapeutics Plc (NASDAQ: ITRM) has experienced a decline in its stock price by -15.08 compared to its previous closing price of 1.26. However, the company has seen a fall of -3.60% in its stock price over the last five trading days. globenewswire.com reported 2025-04-29 that DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded warrant in lieu thereof) in a registered direct offering (the Offering). The closing of the Offering is expected to occur on or about April 30, 2025, subject to the satisfaction of customary closing conditions.
Analysts’ Opinion of ITRM
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITRM reach a price target of $2.50. The rating they have provided for ITRM stocks is “Buy” according to the report published on March 15th, 2021.
RBC Capital Mkts gave a rating of “Sector Perform” to ITRM, setting the target price at $2 in the report published on June 02nd of the previous year.
ITRM Trading at -17.24% from the 50-Day Moving Average
After a stumble in the market that brought ITRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.57% of loss for the given period.
Volatility was left at 8.30%, however, over the last 30 days, the volatility rate increased by 12.22%, as shares sank -13.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.52% lower at present.
During the last 5 trading sessions, ITRM fell by -3.60%, which changed the moving average for the period of 200-days by -27.21% in comparison to the 20-day moving average, which settled at $1.1520. In addition, Iterum Therapeutics Plc saw -39.55% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ITRM
The total capital return value is set at -0.69. Equity return is now at value -555.68, with -69.93 for asset returns.
Based on Iterum Therapeutics Plc (ITRM), the company’s capital structure generated 1.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at -11.16. The interest coverage ratio of the stock is 7.41.
Currently, EBITDA for the company is -18.7 million with net debt to EBITDA at -1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
To sum up, Iterum Therapeutics Plc (ITRM) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
